|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.81 USD | +4.05% |
|
+2.97% | +35.92% |
| 08-06 | Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating | MT |
| 08-06 | RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.55B | - | - | - | ||
| 68.12B | |||||
| 55.18B | |||||
| 28.63B | - | ||||
| 23.99B | |||||
| 23.53B | - |
- Stock Market
- Stocks
- XNCR Stock
- Charts Xencor, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
